ESMO 2022 Conference Coverage


 

ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase II Trial: Avelumab vs. Standard 2L Treatment Chemo in mCRC Patients With Microsatellite Instability

216 views
September 15, 2022
Comments 0
Login to view comments. Click here to Login